Xtandi’s growth trends
In the first nine months of 2018, Pfizer (PFE) and Astellas Pharma’s prostate cancer drug, Xtandi, reported US alliance revenue of $510 million for Pfizer, a YoY (year-over-year) rise of 21%.
In the third quarter, the drug reported alliance revenue of $180 million for Pfizer, a 20% YoY rise and a 5% sequential rise. According to Pfizer’s third-quarter earnings press release, this performance was mainly driven by an increase in the number of urologists prescribing the drug in the metastatic castrate-resistant prostate cancer (or CRPC) indication.
Future growth drivers
On July 13, Pfizer released a press release announcing the FDA’s approval of Xtandi in the non-metastatic CRPC indication. This approval was based on the results of its Phase 3 PROSPER trial.
According to Pfizer’s third-quarter earnings conference call, while the contribution of this new label in Xtandi’s third-quarter sales was modest, the company expects to benefit from this label expansion in the next two years. This timeframe will be required since the non-metastatic CRPC label will enable earlier usage of the drug and will thus lead to a longer duration of therapy.
According to Pfizer’s third-quarter earnings conference call, it’s also witnessed an increase in new-to-brand prescriptions for Xtandi since its FDA approval in the non-metastatic CRPC indication.
On October 29, partner Astellas Pharma released a press release announcing the European Commission’s approval of Xtandi in the non-metastatic CRPC indication.
Astellas Pharma and Pfizer are also studying Xtandi in two Phase 3 trials, EMBARK and ARCHES, for the treatment of hormone-sensitive prostate cancer. As per Astellas Pharma’s press release, the ARCHES trial is expected to conclude in late 2018, while the EMBARK trial will end in mid-2020.
In the next article, we’ll discuss the growth trends for Pfizer’s Eliquis in greater detail.